DR DRTS Alpha Tau Medical Ltd. Loading... : Investor Sentiment and Bull/Bear Views

The author argues Alpha Tau Medical's ~$1.26B market cap with no product revenue already prices in a high probability of success before the ReSTART pivotal trial reports top-line data, which the company guides to late 2026 or early 2027. The FDA approval claim is unsupported because the pivotal trial has not reported and the clinical PMA module still needs that data, while the 100% ORR headline comes from a different 9-patient study. The main risks to the bearish view are a clean ReSTART readout and subsequent FDA approval, Japan reimbursement, and positive REGAIN/IMPACT data; dilution from warrant exercises or future raises is a stated risk.

The author contends that believing DRTS becoming the standard of care for rGBM is already priced in shows a lack of understanding of both the company and the rGBM market. They propose a measurable target of DRTS getting approved for cSCC as a way to track the thesis. The author acknowledges they could be wrong and that things may or may not happen.

The author relays that DRTS's FDA approval is not a done deal, pivotal ReSTART results are guided for late 2026 or early 2027, and at about $1.33B with no revenue the stock already prices in a lot of success after a 275% run. The binary risk sits in the next 3-6 months. This is a cautious/avoid view based on valuation and upcoming binary events.